Clinical trial NCT00203307: A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
Official title: A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Migraine
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
Collaborators: name: Eli Lilly and Company
First posted: 2005-09-20
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study.

The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.


Eligibility criteria: Inclusion Criteria:

* Subjects who are male or female between the ages of 18 and 65, inclusive
* Subjects who have a history of migraine with or without aura as defined by IHS criteria, for at least one year prior to screening
* Subjects who experience between 3 and 10 migraine attacks per month, for the three months preceding screening
* Subjects who have no more than 15 headache days per month
* Subjects who have been on a stable dose (no clinically significant changes) of all daily medications, for any indication, from 28 days prior to screening through the duration of the trial.
* Women who are using, or agree to use for the duration of the study, a medically acceptable form of contraception (as determined by the investigator), if female of childbearing potential.
* Subjects who are able to understand and comply with all study requirements
* Subjects who provide written informed consent prior to any study procedures being performed.

Exclusion Criteria:

* Women who are pregnant or lactating
* Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability (subjects with QTC interval greater than 450ms will be excluded)
* Subjects currently taking, or have taken within the thirty days prior to screening, any neuroleptics \> 1 day per week (such as Geodon, Zyprexa, Compazine, Phenergan, Seroquel and other drugs in the same class)
* Subjects currently taking or have taken within 4-weeks prior to screening any medication for the prevention of migraine
* Subjects who have failed more than two adequate trials of migraine prophylaxis, as determined by investigator
* Subjects who experience significant orthostatic hypotension, as determined by the investigator
* Subjects who, in the investigators opinion, have a history or have evidence of a medical condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
* Subjects who, in the investigators opinion, have a history or have evidence of a psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial.
* Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit

Primary outcomes:
measure: Difference in Migraine Headache Periods During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject.
timeFrame: 84 day period on placebo compared to 84 day period on olanzapine
Secondary outcomes:
measure: Reduction of Migraine Attack Frequency During Each 28-day Interval of the Active Treatment Period as Compared to Each 28-day Interval of the Placebo Treatment Period, Per Subject. Individual Migraine Attacks Are Separated by 48-hours Pain Free Time. A
timeFrame: each 28 day interval of active treatment c ompared to placebo
measure: Reduction in Days Using an Acute Headache Treatment During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject.
timeFrame: 84 day period on olanzapine compared to 84 day period on placebo
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Jefferson Headache Center
state: Pennsylvania
Study officials:
affiliation: Thomas Jefferson University
name: Stephen D Silberstein
role: PRINCIPAL_INVESTIGATOR
References: